PDCD1 and cancer: However, the immune checkpoint inhibitors against the binding of PD-1 with its ligands also result in moderate to severe tissue toxicities in various organs such as lung, skin, small intestine, colon, kidney, liver, pancreas, joints, heart, and vascular system in cancer patients (24–26).